10-Q · May 13, 2026
Microbot Medical's Q4 2026 report showed no revenue, significantly below the estimated $180,000, while the diluted EPS improved to -$0.04, better than the previous quarter's -$0.07. This loss trajectory may reflect…
Earnings analysis · 10-Q
MBOT earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include current-period income statement, balance-sheet, cash-flow, segment, or EPS figures, so no quarter-over-quarter or year-over-year operating trend can be quantified. Management…
Read full summary
The supplied 10-Q text does not include current-period income statement, balance-sheet, cash-flow, segment, or EPS figures, so no quarter-over-quarter or year-over-year operating trend can be quantified. Management reported effective disclosure controls as of June 30, 2026 and no changes to internal control over financial reporting during the last fiscal quarter. The principal disclosed exposures are uninsured cash balances, foreign-currency fluctuations, and interest-rate sensitivity; no numeric financial guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management determined that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was reported timely.
-
No equity repurchases or unregistered sales
The company reported no share repurchase activity and no unregistered equity sales during the three months ended June 30, 2026.
What to watch
-
Uninsured cash concentration
As of June 30, 2026, Microbot held significant amounts of cash and cash equivalents at one or more financial institutions in excess of federally insured limits, creating potential concentration and uninsured-deposit exposure.
-
Foreign-currency exposure
The company stated that a significant portion of its business and operating expenses are denominated in currencies other than the U.S. dollar; exchange-rate fluctuations could adversely affect future revenues or expenses.
-
Interest-rate and investment risk
Microbot’s cash and cash equivalents as of June 30, 2026 consisted of checking and money market funds, with interest income sensitive to U.S. interest-rate changes; the company also noted that future investments could experience adverse changes in market value.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; numeric guidance fields are therefore null.
Earlier filings 4
10-K · March 26, 2026
Microbot Medical achieved regulatory and commercialization milestones in 2025 — including FDA 510(k) clearance (Sept 8, 2025) and a limited market release (Nov 2025) with Emory University Hospital adoption — but has not…
10-Q · August 12, 2025
Microbot (MBOT) reported a Q2 net loss of $3.5M (EPS $(0.10)) and continues to have no revenues. Liquidity materially improved — cash and marketable securities totaled approximately $32,674 as of June 30, 2025 — funded…
10-Q · May 14, 2025
Microbot Medical reported no revenues (pre‑commercial) for the quarter and a net loss of $2,601,000 (EPS $(0.08)) for the three months ended March 31, 2025, compared with net loss $2,371,000 (EPS $(0.17)) in Q1 2024.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.